由于强的Ameluz销售和美国权利收购,Biofrontera在2025年第四季度创下了创纪录的收入和利率,FDA对行动性角质炎治疗的决定预计将于2026年9月发布. Biofrontera hit record revenue and profitability in Q4 2025, fueled by strong Ameluz sales and U.S. rights acquisition, with FDA decision on actinic keratosis treatment expected in September 2026.

生物前沿公司在2025年第四季度报告了创纪录的收入1710万美元,同比增长36%,这是由于获得阿梅鲁兹和RhodoLED全美权利后,Ameluz销售额强并改善运营. Biofrontera reported record revenue of $17.1 million in Q4 2025, a 36% year-over-year increase, driven by stronger Ameluz sales and improved operations after acquiring full U.S. rights to Ameluz and RhodoLED. 公司在第一季度实现了利,净收入为560万美元. 这一新版权结构的推动使成本下降并将毛利率提高到82%. The company posted its first profitable quarter with $5.6 million in net income, boosted by a new royalty structure that cut costs and raised gross margins to 82%. 美国的Ameluz产量每年达到121,000个管,而RhodoLED灯具在686个办公室中增加到745个. Ameluz volume reached 121,000 tubes annually, and RhodoLED lamp placements grew to 745 across 686 offices. 美国食品和药物管理局接受了针对动态角质炎的补充NDA,PDUFA决定预计将于2026年9月发布. The FDA accepted a supplemental NDA for actinic keratosis with a PDUFA decision expected in September 2026. 该公司还获得了1400万美元的融资,并预计2026年毛利率为80%-85%. The company also secured $14 million in funding and expects 2026 gross margins of 80%-85%.